These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 30994521)
1. Fecal Lactoferrin for Assessment of Inflammatory Bowel Disease Activity: A Systematic Review and Meta-Analysis. Dai C; Jiang M; Sun MJ; Cao Q J Clin Gastroenterol; 2020 Jul; 54(6):545-553. PubMed ID: 30994521 [TBL] [Abstract][Full Text] [Related]
2. Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis. Wang Y; Pei F; Wang X; Sun Z; Hu C; Dou H Int J Clin Exp Pathol; 2015; 8(10):12319-32. PubMed ID: 26722419 [TBL] [Abstract][Full Text] [Related]
3. Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients: A systematic review and meta-analysis. Dai C; Jiang M; Sun MJ; Cao Q J Gastroenterol Hepatol; 2018 May; 33(5):990-997. PubMed ID: 29427297 [TBL] [Abstract][Full Text] [Related]
4. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Mosli MH; Zou G; Garg SK; Feagan SG; MacDonald JK; Chande N; Sandborn WJ; Feagan BG Am J Gastroenterol; 2015 Jun; 110(6):802-19; quiz 820. PubMed ID: 25964225 [TBL] [Abstract][Full Text] [Related]
5. Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: a diagnostic meta-analysis. Zhou XL; Xu W; Tang XX; Luo LS; Tu JF; Zhang CJ; Xu X; Wu QD; Pan WS BMC Gastroenterol; 2014 Jul; 14():121. PubMed ID: 25002150 [TBL] [Abstract][Full Text] [Related]
6. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108 [TBL] [Abstract][Full Text] [Related]
8. Optimal Range of Fecal Calprotectin for Predicting Mucosal Healing in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Xiang BJ; Jiang M; Sun MJ; Dai C Visc Med; 2021 Oct; 37(5):338-348. PubMed ID: 34722717 [TBL] [Abstract][Full Text] [Related]
9. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Lin JF; Chen JM; Zuo JH; Yu A; Xiao ZJ; Deng FH; Nie B; Jiang B Inflamm Bowel Dis; 2014 Aug; 20(8):1407-15. PubMed ID: 24983982 [TBL] [Abstract][Full Text] [Related]
10. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983 [TBL] [Abstract][Full Text] [Related]
11. Serum 1,3-beta-D-glucan as a noninvasive test to predict histologic activity in patients with inflammatory bowel disease. Farias E Silva K; Nanini HF; Cascabulho CM; Rosas SLB; Santana PT; Carneiro AJV; Anaissie E; Nucci M; de Souza HSP World J Gastroenterol; 2021 Mar; 27(9):866-885. PubMed ID: 33727775 [TBL] [Abstract][Full Text] [Related]
12. Systematic review with meta-analysis: Time to diagnosis and the impact of delayed diagnosis on clinical outcomes in inflammatory bowel disease. Jayasooriya N; Baillie S; Blackwell J; Bottle A; Petersen I; Creese H; Saxena S; Pollok RC; Aliment Pharmacol Ther; 2023 Mar; 57(6):635-652. PubMed ID: 36627691 [TBL] [Abstract][Full Text] [Related]
13. Fecal lactoferrin, a marker of intestinal inflammation in children with inflammatory bowel disease. Borkowska A; Liberek A; Łuczak G; Jankowska A; Plata-Nazar K; Korzon M; Kamińska B Acta Biochim Pol; 2015; 62(3):541-5. PubMed ID: 26339799 [TBL] [Abstract][Full Text] [Related]
14. Relationship between fecal lactoferrin and inflammatory bowel disease. Dai J; Liu WZ; Zhao YP; Hu YB; Ge ZZ Scand J Gastroenterol; 2007 Dec; 42(12):1440-4. PubMed ID: 17852860 [TBL] [Abstract][Full Text] [Related]
15. Platelet/Albumin ratio and plateletcrit levels are potential new biomarkers for assessing endoscopic inflammatory bowel disease severity. Huang J; Lu J; Jiang F; Song T BMC Gastroenterol; 2023 Nov; 23(1):393. PubMed ID: 37964205 [TBL] [Abstract][Full Text] [Related]
16. Unveiling the Ghrelin and Obestatin Roles in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis Assessing Their Pathogenic Implications and Biomarker Utility. Khalaji A; Babajani N; Amirsardari Z; Saeedian B; Peiman S; Berger NA; Behnoush AH Inflamm Bowel Dis; 2024 Apr; 30(4):629-640. PubMed ID: 37669127 [TBL] [Abstract][Full Text] [Related]
17. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Mao R; Xiao YL; Gao X; Chen BL; He Y; Yang L; Hu PJ; Chen MH Inflamm Bowel Dis; 2012 Oct; 18(10):1894-9. PubMed ID: 22238138 [TBL] [Abstract][Full Text] [Related]
18. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Gisbert JP; McNicholl AG; Gomollon F Inflamm Bowel Dis; 2009 Nov; 15(11):1746-54. PubMed ID: 19363798 [TBL] [Abstract][Full Text] [Related]
19. Resistin, Elastase, and Lactoferrin as Potential Plasma Biomarkers of Pediatric Inflammatory Bowel Disease Based on Comprehensive Proteomic Screens. Louis Sam Titus ASC; Vanarsa K; Soomro S; Patel A; Prince J; Kugathasan S; Mohan C Mol Cell Proteomics; 2023 Feb; 22(2):100487. PubMed ID: 36549591 [TBL] [Abstract][Full Text] [Related]